This trial is for patients who have cancer cells still in the blood or bone marrow after approximately one year of lenalidomide maintenance therapy following a stem cell transplant
Dr. Michael Atkins, a medical oncologist who specializes in melanoma, talks about the results of the DREAMseq trial and how the information will hopefully extend life for more patients with advanced melanoma